Skip to main content
. Author manuscript; available in PMC: 2013 Oct 19.
Published in final edited form as: Pharm Res. 2009 Mar 17;26(6):1516–1524. doi: 10.1007/s11095-009-9864-8

Fig. 5.

Fig. 5

Bcl-2 downregulation by ODN in K562 cells in vitro and in xenograft tumors. a Bcl-2 expression in K562 cells (in vitro) that were untreated, or treated with 1 µM of various ODN formulations, determined by Western blot at 6 h. b Bcl-2 expression in K562 tumors that were untreated, or treated with i.v. injection of 5 mg/kg of various ODN formulations every other day starting on day 7 for a total of seven treatments. Bcl-2 expression was determined at 36 h after the last treatment by Western blot. c Bcl-2 expression in K562 cell clusters that were untreated or treated with free G3139, Tf-LP G3139, or Tf-LP G4126. Bcl-2 expression was determined at 6 h by Western blot.